Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash & Equivalents (2024 - 2025)

Historic Cash & Equivalents for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $103.8 million.

  • Xilio Therapeutics' Cash & Equivalents rose 6938.57% to $103.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.8 million, marking a year-over-year increase of 6938.57%. This contributed to the annual value of $55.3 million for FY2024, which is N/A changed from last year.
  • Xilio Therapeutics' Cash & Equivalents amounted to $103.8 million in Q3 2025, which was up 6938.57% from $121.6 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Cash & Equivalents registered a high of $121.6 million during Q2 2025, and its lowest value of $34.0 million during Q1 2024.